Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-02-27
2010-12-07
Epps-Smith, Janet (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024310, C536S024330
Reexamination Certificate
active
07846906
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
REFERENCES:
patent: 5057417 (1991-10-01), Hammonds et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5861244 (1999-01-01), Wang et al.
patent: 5968748 (1999-10-01), Bennett et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6228642 (2001-05-01), Baker et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6670461 (2003-12-01), Wengel et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2003/0232438 (2003-12-01), Dobie et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: WO 9726270 (1997-07-01), None
patent: WO 9965928 (1999-12-01), None
patent: WO 0116312 (2001-03-01), None
patent: WO 0177384 (2001-10-01), None
patent: WO 0210449 (2002-02-01), None
patent: WO0210449 (2002-02-01), None
patent: WO 0226796 (2002-04-01), None
Branch, 1998, TIBS, pp. 45-50.
Florini et al. Endocrine Review, vol. 17, No. 5, pp. 481-517.
Jen et al. 2000, Stem Cells, vol. 18, pp. 307-319.
Opalinska et al. 2002, Nature Reviews: Drug Discovery, vol. 1, p. 503-514.
Chirila et al. 2002, Biomaterials, vol. 23, pp. 321-342.
Schiavone et al. 2004, Current Pharmaceutical Design, vol. 10, pp. 769-784.
Pellegrini et al. (J. Neurosci. 1996, 16, 8140-8148; see IDS).
GenBank Accession No. NM—000163.1, Nov. 5, 2002.
Hammond, et al., Feb. 2000,Natural, vol. 2, pp. 110-119.
Elbashir, May 2001,Nature, vol. 411, pp. 494-498.
Clemmons, D. R., “IGF Binding Proteins: Regulation of Cellular Actions,”Growth Regulation(1992) 2:80-87.
Rechler, M. M. et al., “Insulin-like Growth Factor Binding Proteins: Gene Structure and Expression,”Growth Regulation(1992) 2:55-68.
Beaudry, A. et al., In Vitro Selection of a Novel Nuclease-Resistanct RNA Phosphodiesterase, Chemistry & Biology, May 2000, pp. 323-334, vol. 7.
Chen, N.-Y. et al., A Growth Hormone Antagonist Protects Mice Against Streptozotocin Induced Glomerulosclerosis Even in the Presence of Elevated Levels of Glucose and Glycated Hemoglobin, Endocrinology, Aug. 5, 1996, pp. 5163-5165, vol. 137.
Coschigano, K. et al., Assessment of Growth Parameters and Life Span of GHR/BP Gene-Disrupted Mice, Endocrinology, Feb. 14, 2000, pp. 2608-2613, vol. 141.
Flyvbjerg, A. et al., Inhibitory Effect of a Growth Hormone Receptor Antagonist (G120K-PEG) on Renal Enlargement, Glomerular Hypertrophy, and Urinary Albumin Excretion in Experimental Diabetes in Mice, Diabetes, 1999, pp. 377-382, vol. 48.
Francisco, et al., A Class of Highly Polymorphic Tetranucleotide Repeats for Canine Genetic Mapping, Mamm. Genome, GenBank Accession No. L78573.1, Nov. 29, 1996.
Friend, K et al., The Growth Hormone Receptor Antagonist Pegvisomant Exhibits Antitumor Activity in Multiple Preclinical Tumor Models, Proceedings of the 200 NCI-EORTC-AACR Symposium, Nov. 2000,.vol. 6 Supplement.
Friend, K., Cancer and the Potential Place for Growth Hormone Receptor Antagonist Therapy, Growth Hormone & IGF Research 2001, pp. S121-S123, Supplement A.
Grant, M., The Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy, Diabetes Care, Apr. 2000, pp. 504-509, vol. 23.
GronbæK, H. et al., Inhibitory Effects of Octreotide on Renal and Glomerular Growth in Early Experimental Diabetes in Mice, Journal of Endocrinology, 2002, pp. 637-643, vol. 172.
Higgins, R. et al., Somatostatin Analogs Inhibit Neonatal Retinal Neovascularization, Exp. Eye Res, 2002, pp. 553-559, vol. 74.
Karpeisky A., et al., Highly Efficient Synthesis of 2-0-Amino Nucleotides and their Incorporation in Hammerhead Ribozymes, Tetrahedron Letters, Mar. 5, 1998, pp. 1131-1134, vol. 39.
Landau, D. et al., A Novel Somatostatin Analogue Prevents Early Renal Complications in the Nonobese Diabetic Mouse, Kidney International, 2001, pp. 505-512, vol. 60.
LeRoith, D. et al., Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor, Endocrine Reviews, 1995, pp. 143-163, vol. 16.
Mertani H C et al., “In situ gene expression of growth hormone (GH) receptor and GH binding protein in adult male rat tissues”, Molecular and Cellular Endocrinology, 1995, pp. 47-61.
Paran, D. et al., A Pilot Study of a Long Acting Somatostatin Analogue for the Treatment of Refractory Rheumatoid Arthritis, Ann. Rheum. Dis., 2001, pp. 888-891, vol. 60.
Paran D. et al., Probable Adverse Effects of Long Term Use of Somatostatin Analogues in Patients with RA, Ann Rheum Dis., 2001, pp. 1117, vol. 61.
Pellegrini, E. et al., Central Administration of a Growth Hormone (GH) Receptor mRNA Antisense Increases GH Pulsatility and Decreases Hypothalamic Somatostatin Expression in Rats, Journal of Neuroscience, Dec. 15, 1996, pp. 8140-8148, vol. 16.
Rubin, R. et al., Biology of Disease-Insuling-Like Growth Factor-I Receptor: Its Role in Cell Proliferation, Apoptosis, and Tumorigenicity, Laboratory Investigation, 1995, pp. 311-331, vol. 73.
Segev, Y. et al., Growth Hormone Receptor Antagonism Prevents Early Renal Changes in Nonobese Diabetic Mice, J. Am., Soc. Nephrol., 1999, pp. 2374-2381, vol. 10.
Serri, O. et al., Somatostatin Analogue, Octreotide, Reduces Increased Glomerular Filtration Rate and Kidney Size in Insulin-Dependent Diabetes, JAMA, Feb. 20, 1991, pp. 888-892, vol. 265.
Sjögren, K. et al., Liver-Derived Insulin-Like Growth Factor I (IGF-I) is the Principal Source of IGF-I in Blood But is Not Required for Postnatal Body Growth in Mice, Proc. Natl. Acad. Sci. USA, Jun. 1999, pp. 7088-792, vol. 96.
Smith, L. et al., Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization, Science, Jun. 13, 1997, pp. 1706-1709, vol. 276.
Tachas G et al., “A GH receptor anit-sense oligonucleotide inhibits hepatic GH receptor expression, 1 GF-I production and body weight gain in normal mice,” Journal of Endocrinology, Apr. 2006, pp. 147-154.
Trainer, P. et al., Treatment of Acromegaly with the Growth Hormone Receptor Antagonist Pegvisomant, The New England Journal of Medicine, Apr. 20, 2000, pp. 1171-1177, vol. 342.
Turnley, A. et al., Suppressor of Cytokine Signaling 2 Regulates Neuronal Differentiation by Inhibiting Growth Hormone Signaling, Nature Neuroscience, Nov. 2002, pp. 1155-1162, vol. 5.
Ullrich, A., et al., Insulin-like Growth Factor I Receptor Primary Structure: Comparision with Insulin Receptor Suggests Structural Determinants that Define Functional Specificity, EMBO J., Jul. 18, 1986, pp. 2503-2512, vol. 5.
Van Der Lely, A., et al., Long-Term Treatment of Acromegaly with Pegvisomant, A Growth Hormone Receptor Antagonist, The Lancet, Nov. 24, 2001, pp. 1754-1759, vol. 358.
Van Neck, J., et al., Dose-Response Effects of a New Growth Hormone Receptor Antagonist (B2036-PEG) on Circulating, Hepatic and Renal Expression of the Growth Hormone/Insulin-Like Growth Factor System in Adult Mice, Journal of Endocrinology, 2000, pp. 295-303, vol. 167.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
New England BioLabs. Inc. Catalogue (1998): 121,284.
Reynolds et al., Rational siRNA design for RNA interference, 2004, Nature Biotechnology, vol. 22, pp. 326-330.
Agrawal et al. Antisense therapeutics: it is as simple as complementary base recognition? Molecule Medicine Today. Feb. 2000, vol. 6, pp. 72-81.
Fuh et al. Rational Design of Potent Antagonists to the Human Growth hormone Receptor. SCIENCE,
Dobie Kenneth
Jain Ravi
Antisense Therapeutics Limited
Epps-Smith Janet
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals, Inc. Patent Dept.
LandOfFree
Modulation of growth hormone receptor expression and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of growth hormone receptor expression and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of growth hormone receptor expression and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178178